Logo

CRIS

Curis, Inc.

CRIS

Curis, Inc. • NASDAQ
$1.37 ▲ 9.60% (+0.12)
Market Cap $17.71 M
52w High $4.53
52w Low $1.02
Dividend Yield 0%
P/E -0.42
Volume 118.53K
Outstanding Shares 12.93M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.176M ▲ $10.085M ▼ $-7.729M ▲ -243.356% ▲ $-0.49 ▲ $-7.687M ▲
Q2-2025 $2.749M ▲ $10.984M ▼ $-8.593M ▲ -312.586% ▲ $-0.68 ▲ $-8.209M ▲
Q1-2025 $2.38M ▼ $12.523M ▲ $-10.616M ▼ -446.05% ▼ $-1.25 $-10.098M ▼
Q4-2024 $3.345M ▲ $12.322M ▼ $-9.618M ▲ -287.534% ▲ $-1.25 ▲ $-7.21M ▲
Q3-2024 $2.931M $13.476M $-10.092M -344.319% $-1.7 $-10.506M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.051M ▼ $27.641M ▼ $42.332M ▼ $-14.691M ▼
Q2-2025 $10.138M ▼ $29.234M ▼ $43.22M ▼ $-13.986M ▼
Q1-2025 $20.282M ▲ $39.326M ▼ $45.933M ▼ $-6.607M ▼
Q4-2024 $19.997M ▼ $41.265M ▼ $47.263M ▼ $-5.998M ▲
Q3-2024 $20.854M $42.473M $51.208M $-8.735M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.729M ▲ $-5.569M ▲ $0 $4.482M ▲ $-1.087M ▲ $-5.569M ▲
Q2-2025 $-8.593M ▲ $-8.009M ▼ $0 $-2.135M ▼ $-10.144M ▼ $-8.009M ▼
Q1-2025 $-10.616M ▼ $-7.252M ▲ $0 ▲ $7.537M ▼ $285K ▲ $-7.252M ▲
Q4-2024 $-9.618M ▲ $-9.26M ▼ $-428K ▼ $8.831M ▲ $-857K ▼ $-9.26M ▼
Q3-2024 $-10.092M $-5.936M $18.318M $-1.524M $10.858M $-5.936M

Revenue by Products

Product Q4-2023Q1-2025Q2-2025Q3-2025
Reportable Segment
Reportable Segment
 $0 ▲$0 ▲$0 ▲$0 ▲
Gross Royalty Revenue
Gross Royalty Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Curis looks like a classic clinical‑stage biotech: almost no product revenue and recurring losses. Revenue has been flat at a very low level for years, so the business is not yet commercially scaled. Operating and net losses are consistent year after year, reflecting ongoing R&D and overhead with no offsetting sales. Earnings per share look extremely negative mainly because of reverse stock splits, not because the underlying dollar losses suddenly exploded. Overall, the income statement shows a company still firmly in the investment phase, dependent on future trial success rather than current profitability.

Balance Sheet

Balance Sheet The balance sheet has been getting lighter over time. Total assets and cash have both trended down, showing that the company is drawing on its financial cushion without fully replenishing it. Debt is minimal, which reduces financial leverage risk, but equity has recently turned negative, a sign of accumulated losses and a thin capital base. The two reverse stock splits over the past years underline pressure on the share price and a need to maintain listing standards. Financially, Curis now looks lean and more fragile than it did a few years ago, with limited room for prolonged setbacks.

Cash Flow

Cash Flow Cash flow reflects steady cash burn. Operating cash outflows have been consistently negative and of similar size over the period, showing a relatively stable spending pattern but no internal cash generation. Capital expenditures are essentially negligible, which is typical for an asset‑light biotech, so nearly all cash use is tied to R&D and operating costs. Free cash flow is therefore clearly negative every year. The company’s ability to keep funding its pipeline will depend on raising external capital or forming partnerships, as current operations do not support themselves.

Competitive Edge

Competitive Edge Curis operates in a highly crowded and fast‑moving oncology space, competing with both large pharmaceuticals and other specialized biotechs. Its main differentiation is a set of targeted, oral, small‑molecule cancer drugs with dual‑mechanism designs, aiming to hit more than one key pathway at once. If clinical data continue to be positive, first‑in‑class positioning in areas like IRAK4 inhibition and oral immune checkpoint modulation could provide a meaningful niche. However, the company’s small size, limited resources, and the presence of well‑funded rivals working on overlapping biology all constrain its competitive strength until it can secure approvals or strong partnership backing.

Innovation and R&D

Innovation and R&D Innovation is the core of Curis’s story. The pipeline centers on orally available, dual‑targeting drugs: emavusertib combining IRAK4 and FLT3 inhibition, fimepinostat combining HDAC and PI3K inhibition, and CA‑170 targeting two immune checkpoints via an oral small molecule. This approach aims to offer both convenience and potentially stronger, more durable responses than single‑target drugs. The company is focusing on genetically defined, harder‑to‑treat cancers, which can support faster regulatory paths if the data are compelling. At the same time, these programs are still subject to the usual clinical risks: safety, efficacy, trial execution, and regulatory uncertainty. Progress in key trials and partnerships will be critical signals for whether the R&D engine is translating into real medical and commercial value.

Summary

Curis is a small, research‑driven oncology company with a promising but unproven pipeline and a financially stretched profile. The income statement shows negligible revenue and persistent losses, typical of a pre‑commercial biotech. The balance sheet has weakened over time, with shrinking cash and assets and now negative equity, highlighting reliance on future financing. Cash flows are consistently negative, with operating cash burn the main drain and no offsetting internal cash generation. On the strategic side, Curis’s main strength is its differentiated, oral, dual‑targeting cancer therapies that could carve out specialized niches if pivotal data are strong. The company has carved out a focused position around novel signaling pathways and genetically defined patient groups, which can be attractive from a medical and regulatory standpoint. The key uncertainties are clinical outcomes, the ability to fund ongoing trials, and competition from larger players in similar indications. Overall, Curis is a high‑risk, high‑dependence‑on‑pipeline‑success biotech story rather than a mature operating business at this stage.

NEWS

November 14, 2025 · 9:26 AM UTC

Curis to Present at Upcoming 30th Annual SNO Meeting

Read more

November 6, 2025 · 4:00 PM UTC

Curis Provides Third Quarter 2025 Business Update

Read more

October 30, 2025 · 4:00 PM UTC

Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

Read more

October 3, 2025 · 4:00 PM UTC

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more

September 2, 2025 · 10:43 AM UTC

Curis to Present at Upcoming Healthcare Conferences in September

Read more